Artificial intelligence is starting to do something cardiology has wanted for decades. Instead of waiting for blocked arteries or a first heart attack to reveal who is at risk, new AI powered blood tests are quietly scanning thousands of molecules in a single sample and turning them into personalized risk maps. The promise is simple but profound: give clinicians many more years of warning and make prevention far more targeted than the blunt tools used today. One such tool, CardiOmicScore, uses a single blood sample to estimate the risk of six major cardiovascular diseases up to 15 years before the first symptoms appear. Additionally, these advancements are being supported by initiatives like the PULSE program, which aims to enhance public health through innovative technologies.
How heart risk has been estimated until now
For most of modern cardiology, blood work has been relatively simple. Clinicians have leaned on cholesterol panels, glucose or HbA1c, and a handful of inflammatory markers such as C reactive protein to gauge who might develop coronary artery disease or stroke. Risk calculators like the ASCVD or Reynolds scores then combine age, sex, blood pressure, cholesterol and a few clinical variables into a ten year risk estimate.
For decades, cardiology has relied on basic labs and coarse ten‑year cardiovascular risk scores
These tools work at the population level, but they have clear limitations. Many people with “normal” cholesterol still develop heart disease, while others with high readings never do. The models are coarse, often divide patients into only a few risk buckets, and were built for an era when rich molecular data were not available.
The new AI blood tests are a reaction to those constraints. Instead of looking at a handful of lab values, they ingest dense molecular snapshots and learn patterns that humans would struggle to see.
CardiOmicScore and the move to multiomic risk maps
One of the most ambitious efforts is CardiOmicScore, developed using the UK Biobank and multiomic profiles from a single blood draw. The framework uses deep learning models trained on thousands of proteins and hundreds of metabolites to estimate the risk of six major cardiovascular diseases, including coronary artery disease, stroke, heart failure, atrial fibrillation, peripheral artery disease and venous thromboembolism.
In large cohort analyses, CardiOmicScore has shown the ability to flag individuals at elevated risk as far as fifteen years before clinical onset of these conditions. The system generates disease specific risk scores by combining two neural network models, one focused on metabolomic data and another on proteomic data, and then integrates these with traditional clinical factors.
In head to head comparisons, these multiomic scores have outperformed conventional risk calculators that rely only on clinical indicators and standard lipids.
It is important to see CardiOmicScore for what it is today. The Nature Communications study and related analyses present a proof of concept that deep learning can extract complementary signal from complex omics that adds meaningful predictive power beyond established scores. That is very different from saying the test is ready for routine use everywhere. The training data come largely from a specific biobank population, and the framework still needs broad external validation across diverse health systems and ancestries.
HART CVE and near term event prediction
If CardiOmicScore is about widening the temporal window, HART CVE is about the next year of a patient’s life. Developed by Prevencio with collaborators at Massachusetts General Hospital, HART CVE is a multi protein blood test that uses a machine learning algorithm to estimate the one year risk of major adverse cardiovascular events, namely heart attack, stroke or cardiovascular death.
The panel measures four proteins that capture different aspects of cardiovascular stress and injury: NT proBNP for cardiac wall stress, osteopontin for calcification and plaque biology, kidney injury molecule 1 for cardio renal and vascular injury, and TIMP 1 as a marker of matrix remodeling and plaque rupture tendency. These values are combined algorithmically into a risk score typically scaled from zero to ten, which is then grouped into tiers such as low, intermediate and high risk.
In validation studies, HART CVE has demonstrated an area under the receiver operating characteristic curve around 0 point 79 to 0 point 86 for predicting one year events, which compares favorably with standard clinical risk assessments in similar populations. Perhaps the most clinically relevant statistic is its negative predictive value. In several cohorts, a low score has been associated with a roughly 97 to 99 percent probability that a patient will not suffer a major cardiac event within one year.
That makes the test particularly attractive as a rule out tool for symptomatic but lower risk patients or for follow up in those with multiple risk factors but no established disease. Prevencio has pursued regulatory and commercial pathways, positioning HART CVE as a laboratory developed test that clinicians can order today, especially for patients with diabetes, obesity, chronic kidney disease or a strong family history of heart disease.
This is notable because many AI models remain confined to academic papers, while HART CVE is one of the few that has matured into a marketed cardiac risk blood test.
Beyond single markers: what is inside these AI blood tests
The generational shift here is less about any one biomarker and more about how many layers of biology are fused together.
Traditional cardiac blood tests have focused on single classes of molecules. Natriuretic peptides such as BNP and NT proBNP capture myocardial stretch and heart failure risk. High sensitivity troponins reveal myocardial injury and correlate with coronary artery disease risk even in asymptomatic individuals. Inflammatory markers like high sensitivity C reactive protein offer a window into systemic inflammation and future events.
AI based platforms extend this by layering:
- Protein panels that include markers of fibrosis, remodeling and systemic stress, such as galectin 3, growth differentiation factor 15, soluble ST2 and others alongside natriuretic peptides and troponins.
- Transcriptomic signals, especially microRNAs that are released during myocardial injury or vascular remodeling. Multiple studies have shown that microRNAs such as miR 1, miR 21, miR 133 and miR 499 carry diagnostic and prognostic information for acute coronary syndromes and stable coronary artery disease.
- Specific emphasis on miR 21, which has been repeatedly reported as elevated in myocardial infarction, heart failure and coronary artery disease, and has shown pooled sensitivities and specificities near 0 point 8 for differentiating acute events from controls in meta analyses.
- Whole blood transcriptome signatures and compact gene expression panels that can separate obstructive from non obstructive disease and even capture early heart failure phenotypes.
When these layers are combined with metabolomic profiles and standard laboratory data, machine learning models can infer evolving cardiovascular risk states that would never trigger an alarm on a standard lipid panel or basic troponin check. This is exactly what CardiOmicScore demonstrates at scale: metabolomic and proteomic risk scores add independent predictive value beyond clinical risk factors across multiple cardiovascular endpoints.
How good are these models in real terms
Numbers like 96 percent accuracy or AUC above 0 point 85 sound impressive, but they are easy to misinterpret without context.
For coronary artery disease and related conditions, a variety of machine learning models using structured biomarker panels plus vital signs have reported diagnostic accuracies in the range of seventy percent and higher, with some transcriptomic or microRNA based approaches reporting values in the mid nineties within specific cohorts. Those figures often come from carefully selected populations and may not hold in broader, more heterogeneous groups.
For HART CVE, the AUC values around 0 point 8 and the very high negative predictive value in low scoring patients are clinically meaningful, but the positive predictive value is more modest. In some analyses, a high risk HART CVE score corresponds to only about a one in three chance of a major event within a year. That is typical in preventive cardiology, where events are thankfully rare, and it underlines a key point: these tests are often more powerful for ruling out near term risk than for pinpointing exactly who will have an event.
For CardiOmicScore, the advantage is in extending the prediction horizon and refining risk gradients rather than achieving perfect classification. The addition of multiomic risk scores meaningfully improves discrimination and risk reclassification compared with standard clinical models, but there is still considerable uncertainty at the individual level, especially more than a decade before disease onset.
A trustworthy view must acknowledge this: AI blood tests are improving the odds of getting risk right, not eliminating uncertainty.
What this means for clinicians, health systems and patients
If AI powered blood tests continue to validate in diverse settings, they could reshape several parts of cardiovascular care.
For frontline clinicians, these tools offer richer risk stratification with a familiar workflow: draw blood, receive a score, interpret it in context. A high short term risk from a test such as HART CVE might push toward earlier imaging, more aggressive lipid and blood pressure management, or closer follow up. A very low score could support conservative management and avoid over testing in crowded emergency departments or outpatient clinics.
For health systems, early data suggest a path to reallocating resources. Identifying high risk individuals many years before symptoms with tests like CardiOmicScore could justify concentrating preventive programs, lifestyle coaching and novel therapies on the people most likely to benefit. At the same time, reliably identifying those at very low near term risk can reduce unnecessary admissions and imaging.
For patients, the impact is psychological as well as clinical. A graded, personalized risk trajectory tends to be more motivating than a vague label of “borderline risk.” Seeing a multi year risk curve shift after sustained lifestyle changes or medication adherence can make risk reduction tangible in a way that single cholesterol numbers struggle to do.
It is also important not to overstate readiness. Many of the most advanced multiomic models are still research tools. They must prove themselves across different ethnicities, comorbidity patterns and healthcare systems, and they need cost effectiveness data before payers will reimburse them at scale.
Risks, blind spots and open questions
With any high capacity AI model, especially in medicine, the failure modes are as important as the headline accuracies.
- Data bias and generalizability. Multiomic models trained primarily on European ancestry biobank participants may perform less well in underrepresented populations, potentially widening disparities if adopted uncritically.
- Overfitting and reproducibility. Rich molecular datasets can encourage subtle overfitting, where a model learns noise or cohort specific quirks. Robust external validation and prospective trials are essential.
- Interpretability. Many of these models function as black boxes. While individual biomarkers may have known biology, the combined risk score is often not easily interpretable, which can challenge clinician trust and informed consent.
- Over screening and anxiety. Highly sensitive tests risk labeling large numbers of people as “at risk,” driving cascades of further testing and treatment with unclear benefit and real costs.
- Regulatory and commercial pressure. When tests are commercialized early, as with HART CVE, marketing narratives can get ahead of evidence. That places a premium on independent validation and transparent reporting of both strengths and limitations.
Addressing these issues will require careful trial design, open data where possible, and clear guidance from professional societies on how to integrate AI derived scores into existing guidelines rather than replacing them overnight.
Key takeaways and what to watch next
- AI powered blood tests are moving cardiology from coarse, decade scale risk estimates based on a few clinical variables toward personalized, multiomic risk trajectories spanning the next year to the next fifteen years.
- CardiOmicScore showcases how deep learning applied to thousands of proteins and metabolites can improve prediction of multiple cardiovascular diseases long before symptoms appear, but remains at an advanced research stage rather than a routine clinical assay.
- HART CVE demonstrates that a focused multi protein panel combined with machine learning can deliver a commercially available test with strong short term rule out power for major cardiac events, though its positive predictive value is modest and must be interpreted carefully.
- Emerging RNA and transcriptome based markers, especially microRNAs such as miR 21, miR 133 and miR 499, add sensitivity for early myocardial injury and may further refine risk when integrated into larger models.
- The biggest opportunities lie in earlier, more individualized prevention and smarter allocation of resources, while the biggest risks involve bias, overuse and premature commercialization without adequate validation.
Over the next few years, expect to see more prospective trials that embed AI blood tests into real world pathways, from emergency chest pain evaluation to primary care risk screening. The tests that succeed will not be those with the flashiest machine learning architecture, but those that show clear, reproducible benefit when layered onto the messy reality of everyday cardiology practice.
Conclusion
Heart disease has long been treated as something that reveals itself only when symptoms finally show up, often in the emergency room rather than the clinic. An emerging generation of AI powered blood tests is starting to challenge that assumption by turning a routine vial of blood into a long range forecast of cardiovascular risk that can stretch more than a decade into the future.
How we got here
For most of modern cardiology, risk prediction has relied on a handful of familiar indicators. Clinicians look at age, blood pressure, cholesterol, smoking status and diabetes, then plug these into calculators derived from large epidemiological studies such as Framingham. These tools have helped guide statin prescriptions and lifestyle advice, but they only offer a coarse probability of an event over the next few years, and they often miss people who appear healthy on paper yet carry silent disease in their arteries.
Over the past decade, cardiology has moved from simple scores to richer data. Imaging techniques such as coronary calcium scans and echocardiograms, along with genetic and biomarker profiling, have improved the ability to identify high risk individuals earlier. Artificial intelligence has accelerated this shift by finding subtle patterns in electrocardiograms, medical images and electronic health records that humans cannot easily see. Several teams have already shown that AI models can detect structural heart disease or predict heart failure rehospitalization before traditional tests raise alarms.
Blood based prediction is the latest step in this evolution. Instead of relying on one or two markers like cholesterol or high sensitivity troponin, researchers now measure hundreds of proteins or epigenetic signals and let machine learning models learn which combinations forecast future events.
What the new AI blood tests actually do
A recent example is a system known as CardiOmicScore, which uses information from a single standard blood draw to estimate a persons future risk of six major cardiovascular conditions. These include coronary artery disease, stroke, heart failure, atrial fibrillation, peripheral artery disease and venous thromboembolism. In people who already have elevated risk, the model can flag warning signals as far as fifteen years before the clinical onset of disease.
The CardiOmicScore approach is built on the idea that the bloodstream carries a molecular signature of ongoing processes in the vasculature and heart that begin long before symptoms such as chest pain or shortness of breath. By training an AI model on blood samples linked to long term outcomes, researchers can identify high dimensional patterns that correlate with future events even when classical lab values are still within normal ranges.
This long horizon is complemented by shorter term prediction tools. A patented AI driven test called HART CVE analyzes a panel of proteins to estimate a patients one year risk of heart attack, stroke or cardiovascular death. When its score is divided into low risk and high risk categories, the test predicts with about ninety eight percent negative predictive value that a low risk patient will not suffer a major cardiovascular event within one year. A companion test, HART CADhs, uses a multi protein blood panel to diagnose obstructive coronary artery disease with higher accuracy than traditional stress tests, achieving an area under the curve of around eighty six percent compared with about fifty two percent for standard care.
Other research groups are pushing the concept further using epigenetic biomarkers. These assays look at chemical modifications to DNA that reflect cumulative exposure to lifestyle and environmental factors. Routine blood draws can be used to detect epigenetic signatures associated with future cardiovascular disease and feed them into AI models for more refined risk stratification.
These efforts sit within a broader landscape of AI for cardiovascular risk. Reviews of the field show that machine learning algorithms have been used to improve the timing and accuracy of diagnosis for conditions such as atrial fibrillation, valvular disease and cardiomyopathy, often by combining image analysis, waveform data and structured clinical information. Explainable AI systems using techniques such as gradient boosting and multilayer perceptrons have achieved testing accuracies around ninety to ninety two percent in predicting cardiovascular disease from structured datasets, illustrating how data driven models can match or exceed traditional methods.
Why predicting fifteen years ahead matters
The ability to see elevated risk fifteen years before symptoms is not just a technical achievement. It changes the timeline on which clinicians and patients can act.
Today, many people first learn they have heart disease when they arrive at an emergency department with a heart attack or stroke. At that moment, there is limited opportunity to modify long term trajectories. If a routine blood test taken in midlife could reliably show that someone sits in the highest risk band for several major cardiovascular diseases, it would create a new window for preventive care.
That window would allow clinicians to consider earlier use of proven interventions, from more aggressive lipid lowering and blood pressure control to weight management and smoking cessation programs. It might also support more targeted deployment of newer therapies such as PCSK9 inhibitors or anti inflammatory agents for those whose blood signatures suggest they will benefit most.
From a public health perspective, the difference between intervening five years before an event and fifteen years before may mean the difference between a single prevented heart attack and an entirely avoided chronic disease trajectory. Longitudinal risk signals could inform how healthcare systems design screening intervals, how insurers structure preventive benefits and how employers invest in cardiovascular wellness programs.
There is also a psychological aspect. Seeing a personalized risk score tied to molecular data, rather than a generic label based on age and cholesterol, can motivate behavioral change. Some patients respond more strongly to a concrete forecast that says they are in the highest percentile for future coronary disease than to abstract advice about diet and exercise.
Technical foundations and the reality behind the numbers
Under the surface, these AI blood tests rely on familiar machine learning principles applied to unusually rich data. Researchers collect large cohorts with banked blood samples, often from biobanks or long running observational studies, along with detailed follow up on cardiovascular outcomes. They then measure hundreds or thousands of biomarkers in each sample, including proteins, lipids and epigenetic marks, and feed these into algorithms that learn nonlinear relationships between baseline molecular profiles and future events.
Models such as gradient boosted trees and deep neural networks are popular because they can handle complex feature interactions and class imbalance, which is common when serious events are relatively rare in the training data. Work on explainable AI driven systems for precision cardiovascular care has shown that tree based models such as LightGBM can achieve testing accuracies above ninety percent while still allowing some insight into which features drive predictions. Enhanced multilayer perceptron frameworks evaluated on survey data from the Centers for Disease Control have reached around ninety two percent accuracy in classifying cardiac disease, suggesting that neural networks can also be tuned to this domain.
It is important to treat these numbers with care. Performance metrics such as area under the curve, sensitivity and specificity depend heavily on the population studied, the prevalence of disease and the choice of thresholds. A model trained in a tertiary care setting may perform differently in a primary care environment. External validation across diverse cohorts is essential before clinical deployment.
Bias is another central concern. Analyses of AI for cardiovascular prediction warn that models can inherit and amplify inequities if they are trained on datasets that underrepresent certain ethnic groups, socioeconomic strata or regions. If an AI blood test is primarily trained on patients from well resourced health systems, its predictions may be less reliable for people who do not match that profile. Addressing this requires deliberate inclusion of diverse populations, careful monitoring for differential performance and transparency about limitations.
Implications for health systems and the AI ecosystem
If AI powered blood tests become routine, they will reshape workflows in both clinical practice and the broader health industry.
For hospitals and clinics, the most immediate change would be a shift from opportunistic testing to structured longitudinal cardiovascular surveillance. Primary care physicians might order a comprehensive AI interpreted blood panel at specific ages, much as they do colonoscopies or mammograms. Cardiologists could use these scores to triage which patients merit further imaging or intensive management, prioritizing those with the highest projected risk.
Laboratories and diagnostics companies stand to gain new roles as platforms for AI enabled assays. Tests such as HART CVE and HART CADhs already illustrate how companies can patent and commercialize multi protein blood panels integrated with predictive algorithms. Wider adoption of epigenetic and proteomic tests for cardiovascular risk would create demand for high throughput molecular measurement technologies and robust data infrastructures to store and analyze results at scale.
Technology firms working in healthcare AI will see opportunities to partner with labs, hospital systems and electronic record vendors to integrate predictions into clinical decision support. This integration is nontrivial. It requires interfaces that present risk scores in intuitive ways, highlight the evidence behind them and avoid overwhelming clinicians with alerts. It also requires governance structures to manage model updates, version control and regulatory compliance.
For insurers and payers, long range forecasts of cardiovascular risk could influence underwriting and benefit design. There is a real tension here. On one hand, better prediction can support early preventive coverage that reduces long term costs. On the other hand, there is a risk that risk scores could be misused to deny coverage or raise premiums if safeguards are not in place. Policy frameworks will need to clarify how such data can be used ethically.
Ethics, access and trust
Any technology that predicts disease years before symptoms raises deep ethical questions. AI blood tests for heart disease are no exception.
Access is a fundamental issue. If these assays are expensive or only available in advanced centers, they may primarily benefit affluent patients and widen existing disparities in cardiovascular outcomes. Ensuring that predictive testing does not become a luxury service requires attention to reimbursement, public health infrastructure and global deployment strategies.
Consent and privacy matter as well. A test that analyzes a rich molecular profile and feeds it into an AI model is generating sensitive information about a persons health future. Patients must understand what is being measured, how the data will be used and who can see the predictions. Deidentification and secure data handling are necessary but not sufficient; there must be clear communication and shared decision making.
False positives and false negatives carry real consequences. Overestimating risk can lead to anxiety, unnecessary procedures and side effects from medications. Underestimating risk can lull patients and clinicians into complacency. The balance between sensitivity and specificity should be tailored to clinical contexts, and models should be monitored over time to ensure they perform as expected.
Trust will ultimately depend on transparency and evidence. Clinicians will want to see prospective trial data showing that acting on AI blood test results actually reduces events, not just that the scores correlate with outcomes. Patients will want assurances that the tools have been evaluated across populations like theirs, that they do not encode hidden biases and that predictions can be explained in understandable terms.
Looking ahead
Taken together, the emergence of AI supported blood tests that can anticipate cardiovascular risk years before symptoms reframes heart disease as a condition that can be actively intercepted rather than passively endured. By turning a single routine sample into a long range warning system, these tools shift attention toward earlier lifestyle changes and more precise use of therapies, provided that health systems are willing and able to incorporate them into care pathways. Whether they truly deliver fewer sudden crises and longer healthier lives will depend on robust validation, thoughtful regulation, equitable access and sustained collaboration between clinicians, technologists and policymakers. The promise is transformative, but realizing it will require careful work rather than simple faith in algorithms, and the next decade of cardiovascular medicine will show how well we rise to that challenge reddit
